JP2023058590A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2023058590A5 JP2023058590A5 JP2023017271A JP2023017271A JP2023058590A5 JP 2023058590 A5 JP2023058590 A5 JP 2023058590A5 JP 2023017271 A JP2023017271 A JP 2023017271A JP 2023017271 A JP2023017271 A JP 2023017271A JP 2023058590 A5 JP2023058590 A5 JP 2023058590A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- antibody
- binding fragment
- poly
- heavy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims 15
- 102000036639 antigens Human genes 0.000 claims 15
- 108091007433 antigens Proteins 0.000 claims 15
- 239000012634 fragment Substances 0.000 claims 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 210000004027 cell Anatomy 0.000 claims 5
- 230000003247 decreasing effect Effects 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 3
- 206010065687 Bone loss Diseases 0.000 claims 2
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 2
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims 2
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims 2
- 210000000988 bone and bone Anatomy 0.000 claims 2
- 239000013604 expression vector Substances 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 102000004196 processed proteins & peptides Human genes 0.000 claims 2
- 101500025614 Homo sapiens Transforming growth factor beta-1 Proteins 0.000 claims 1
- 101500025624 Homo sapiens Transforming growth factor beta-2 Proteins 0.000 claims 1
- 101500026551 Homo sapiens Transforming growth factor beta-3 Proteins 0.000 claims 1
- 208000008839 Kidney Neoplasms Diseases 0.000 claims 1
- 208000029725 Metabolic bone disease Diseases 0.000 claims 1
- 206010027476 Metastases Diseases 0.000 claims 1
- 206010031243 Osteogenesis imperfecta Diseases 0.000 claims 1
- 206010049088 Osteopenia Diseases 0.000 claims 1
- 208000001132 Osteoporosis Diseases 0.000 claims 1
- 229920000805 Polyaspartic acid Polymers 0.000 claims 1
- 206010038389 Renal cancer Diseases 0.000 claims 1
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims 1
- 230000037182 bone density Effects 0.000 claims 1
- 230000037118 bone strength Effects 0.000 claims 1
- 208000020832 chronic kidney disease Diseases 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 230000005764 inhibitory process Effects 0.000 claims 1
- 201000010982 kidney cancer Diseases 0.000 claims 1
- 210000004962 mammalian cell Anatomy 0.000 claims 1
- 230000009401 metastasis Effects 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 108010064470 polyaspartate Proteins 0.000 claims 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024205967A JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762448763P | 2017-01-20 | 2017-01-20 | |
| US62/448,763 | 2017-01-20 | ||
| JP2019539277A JP7227138B2 (ja) | 2017-01-20 | 2018-01-19 | 骨標的抗体 |
| PCT/US2018/014350 WO2018136698A2 (en) | 2017-01-20 | 2018-01-19 | Bone-targeting antibodies |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539277A Division JP7227138B2 (ja) | 2017-01-20 | 2018-01-19 | 骨標的抗体 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024205967A Division JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023058590A JP2023058590A (ja) | 2023-04-25 |
| JP2023058590A5 true JP2023058590A5 (https=) | 2023-06-13 |
| JP7597836B2 JP7597836B2 (ja) | 2024-12-10 |
Family
ID=61581744
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539277A Active JP7227138B2 (ja) | 2017-01-20 | 2018-01-19 | 骨標的抗体 |
| JP2023017271A Active JP7597836B2 (ja) | 2017-01-20 | 2023-02-08 | 骨標的抗体 |
| JP2024205967A Pending JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019539277A Active JP7227138B2 (ja) | 2017-01-20 | 2018-01-19 | 骨標的抗体 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024205967A Pending JP2025028981A (ja) | 2017-01-20 | 2024-11-27 | 骨標的抗体 |
Country Status (17)
| Country | Link |
|---|---|
| US (3) | US10844115B2 (https=) |
| EP (1) | EP3571226A2 (https=) |
| JP (3) | JP7227138B2 (https=) |
| KR (3) | KR102613463B1 (https=) |
| CN (2) | CN111032690B (https=) |
| AR (1) | AR110755A1 (https=) |
| AU (1) | AU2018210270A1 (https=) |
| BR (1) | BR112019013986A2 (https=) |
| CA (1) | CA3050884A1 (https=) |
| IL (2) | IL268114B2 (https=) |
| MX (2) | MX2019008549A (https=) |
| MY (2) | MY194819A (https=) |
| SG (1) | SG11201906663VA (https=) |
| TW (3) | TWI832600B (https=) |
| UY (1) | UY37576A (https=) |
| WO (1) | WO2018136698A2 (https=) |
| ZA (1) | ZA201907673B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2017310344A1 (en) * | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) * | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
| WO2019232283A1 (en) | 2018-05-30 | 2019-12-05 | Purdue Research Foundation | Targeting anabolic drugs for accelerated fracture repair |
| KR20210030411A (ko) * | 2018-07-10 | 2021-03-17 | 사노피 | Cd38 및 tgf-베타를 표적으로 하는 암에 대한 병용 요법 |
| JP2022513079A (ja) * | 2018-11-19 | 2022-02-07 | バイオカルティス エン フェー | 統合ワークフローでの低コピー数の核酸の強化された検出 |
| CA3219219A1 (en) | 2021-05-07 | 2022-11-10 | Baylor College Of Medicine | Treatment of moderate-to-severe osteogenesis imperfecta |
| CA3226401A1 (en) * | 2021-07-20 | 2023-01-26 | William Marsh Rice University | Engineered compositions for bone-targeted therapy |
| MX2024005344A (es) | 2021-11-01 | 2024-07-19 | Genzyme Corp | Tratamiento de la osteogenesis imperfecta. |
| CN115403657A (zh) * | 2022-06-23 | 2022-11-29 | 浙江大学 | 一种TGF-β3生长因子的亲和多肽及其应用 |
| AU2024229931A1 (en) | 2023-02-27 | 2025-09-11 | The Trustees Of Columbia University In The City Of New York | Bone-directed therapeutics for the treatment of cancer |
| JP7479537B1 (ja) * | 2023-03-31 | 2024-05-08 | ナガヨシ製薬株式会社 | 咳を止め、痰を減らし、免疫力を向上させるイナゴマメ多糖類およびその調製方法と使用 |
| WO2025184427A1 (en) * | 2024-02-27 | 2025-09-04 | Osteologic Therapeutics, Inc. | Bone-targeted antibodies and methods of use thereof |
| CN120647762B (zh) * | 2025-06-16 | 2026-01-23 | 首都医科大学附属北京友谊医院 | 一种抗β1-AR-ECII抗体及其应用 |
| CN120535618B (zh) * | 2025-07-28 | 2025-09-23 | 成都大熊猫繁育研究基地 | 一种抗大熊猫cdv单克隆抗体、杂交瘤细胞株及用途 |
Family Cites Families (54)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4867973A (en) | 1984-08-31 | 1989-09-19 | Cytogen Corporation | Antibody-therapeutic agent conjugates |
| US4671958A (en) | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
| US5571714A (en) | 1988-12-22 | 1996-11-05 | Celtrix Pharmaceuticals, Inc. | Monoclonal antibodies which bind both transforming growth factors β1 and β2 and methods of use |
| ES2156149T3 (es) | 1992-12-04 | 2001-06-16 | Medical Res Council | Proteinas de union multivalente y multiespecificas, su fabricacion y su uso. |
| US5824655A (en) | 1995-02-15 | 1998-10-20 | The University Of Utah | Anti-transforming growth factor-β gene therapy |
| GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
| MX336813B (es) | 1996-02-09 | 2016-02-02 | Abbvie Biotechnology Ltd | Anticuerpos humanos que ligan el tnfa humano. |
| US6455495B1 (en) | 1997-02-14 | 2002-09-24 | The Salk Institute For Biological Studies | Methods and compositions for delivery of therapeutic agents to bone tissue employing conjugates of negatively charged peptide oligomers with therapeutic agents |
| EP1074563A1 (en) * | 1999-08-02 | 2001-02-07 | F. Hoffmann-La Roche Ag | Chimeric polypeptides enhancing dimer formation through electrostatic interactions and disulfide bond, method for production and uses thereof |
| US20030224501A1 (en) | 2000-03-17 | 2003-12-04 | Young Paul E. | Bone morphogenic protein polynucleotides, polypeptides, and antibodies |
| JP2006523609A (ja) | 2002-12-31 | 2006-10-19 | アルタス ファーマシューティカルズ インコーポレイテッド | タンパク質結晶およびイオン性ポリマーの複合体 |
| JP2006525362A (ja) | 2003-04-30 | 2006-11-09 | ジェンザイム コーポレーション | 腎機能不全を治療するためのＴＧＦ−βアンタゴニストとレニン−アンジオテンシン−アルドステロン系アンタゴニストとの併用 |
| WO2005010049A2 (en) | 2003-07-09 | 2005-02-03 | Eli Lilly And Company | Tgf-beta1 ligands |
| EP1740615B1 (en) | 2004-03-31 | 2014-11-05 | Genentech, Inc. | Humanized anti-tgf-beta antibodies |
| CA2559228C (en) | 2004-04-21 | 2016-06-21 | Enobia Pharma Inc. | Bone delivery conjugates and method of using same to target proteins to bone |
| TR201901929T4 (tr) | 2005-02-08 | 2019-03-21 | Genzyme Corp | TGFBeta'ya antikorlar. |
| TW200714289A (en) * | 2005-02-28 | 2007-04-16 | Genentech Inc | Treatment of bone disorders |
| EP1966243B1 (en) * | 2005-12-23 | 2012-02-15 | Eli Lilly And Company | Tgf-beta binding antibodies |
| JP6071165B2 (ja) | 2007-05-31 | 2017-02-01 | ゲンマブ エー／エス | 安定なＩｇＧ４抗体 |
| US8574577B2 (en) * | 2008-01-03 | 2013-11-05 | The Scripps Research Institute | VEGF antibodies comprising modular recognition domains |
| KR101658247B1 (ko) | 2008-01-03 | 2016-09-22 | 더 스크립스 리서치 인스티튜트 | 모듈 인식 도메인을 통한 항체 표적화 |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| WO2010072691A1 (en) | 2008-12-22 | 2010-07-01 | Novo Nordisk A/S | Antibodies against tissue factor pathway inhibitor |
| WO2010124276A2 (en) | 2009-04-24 | 2010-10-28 | Vanderbilt Universtiy | Anti-tgf-beta induction of bone cell function and bone growth |
| CA3253628A1 (en) | 2010-03-05 | 2025-11-29 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| ES2692268T5 (en) | 2011-03-29 | 2025-02-26 | Roche Glycart Ag | Antibody fc variants |
| JP6072771B2 (ja) | 2011-04-20 | 2017-02-01 | メディミューン，エルエルシー | Ｂ７−ｈ１およびｐｄ−１に結合する抗体およびその他の分子 |
| CN103732623B (zh) | 2011-06-03 | 2017-09-29 | 佐马技术有限公司 | 对TGF‑β具有特异性的抗体 |
| EP2718325A4 (en) | 2011-06-13 | 2015-03-11 | ABGENOMICS COöPERATIEF U A | ANTI-PSGL-1 ANTIBODIES AND USES THEREOF |
| KR20140084201A (ko) | 2011-10-19 | 2014-07-04 | 알렉시온 파마 홀딩 | 알칼리성 포스파타제 및/또는 나트륨이뇨 펩티드를 포함하는 조성물 및 그의 사용 방법 |
| US9592289B2 (en) | 2012-03-26 | 2017-03-14 | Sanofi | Stable IgG4 based binding agent formulations |
| US10052366B2 (en) * | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
| WO2013178736A1 (en) | 2012-05-31 | 2013-12-05 | Innate Pharma | Tlr3 binding agents |
| US9682143B2 (en) | 2012-08-14 | 2017-06-20 | Ibc Pharmaceuticals, Inc. | Combination therapy for inducing immune response to disease |
| CA2886607A1 (en) | 2012-10-17 | 2014-04-24 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| HRP20181939T4 (hr) * | 2013-03-20 | 2022-05-13 | Genzyme Corporation | Postupci za liječenje osteogenesis imperfecta |
| RS61778B1 (sr) | 2013-05-06 | 2021-06-30 | Scholar Rock Inc | Kompozicije i postupci za modulaciju faktora rasta |
| CN112552401B (zh) | 2013-09-13 | 2023-08-25 | 广州百济神州生物制药有限公司 | 抗pd1抗体及其作为治疗剂与诊断剂的用途 |
| JP2017507900A (ja) | 2013-12-17 | 2017-03-23 | ジェネンテック， インコーポレイテッド | Ｐｄ−１軸結合アンタゴニスト及び抗ｈｅｒ２抗体を使用してｈｅｒ２陽性がんを治療する方法 |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| US20170216401A1 (en) * | 2014-03-17 | 2017-08-03 | Piotr Jachimczak | Combination for use in a method of treating cancer |
| CN107428825A (zh) | 2014-10-10 | 2017-12-01 | 创祐生技股份有限公司 | 治疗及/或预防肿瘤生长、侵袭及/或转移的方法 |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗ｐｄ－１抗體類和使用彼等之方法 |
| US11786457B2 (en) | 2015-01-30 | 2023-10-17 | President And Fellows Of Harvard College | Peritumoral and intratumoral materials for cancer therapy |
| TWI733661B (zh) | 2015-03-04 | 2021-07-21 | 美商健臻公司 | 以高親合性、結合性及特異性結合轉化生長因子－β１的經修飾ＩｇＧ抗體 |
| EP3770171A1 (en) | 2015-04-03 | 2021-01-27 | XOMA Technology Ltd. | Treatment of cancer using inhibitors of tgf-beta and pd-1 |
| KR20250004095A (ko) | 2015-04-17 | 2025-01-07 | 브리스톨-마이어스 스큅 컴퍼니 | 항-pd-1 항체 및 또 다른 항체의 조합물을 포함하는 조성물 |
| WO2017011773A2 (en) * | 2015-07-15 | 2017-01-19 | Modernatx, Inc. | Codon-optimized nucleic acids encoding antibodies |
| US20200231652A1 (en) * | 2015-08-31 | 2020-07-23 | National Research Council Of Canada | Tgf-b-receptor ectodomain fusion molecules and uses thereof |
| AU2017310344A1 (en) | 2016-08-11 | 2019-03-07 | Precithera, Inc. | TGF-β antagonist conjugates |
| TWI787230B (zh) | 2017-01-20 | 2022-12-21 | 法商賽諾菲公司 | 抗ＴＧＦ-β抗體及其用途 |
| TWI832600B (zh) | 2017-01-20 | 2024-02-11 | 美商健臻公司 | 骨靶向抗體 |
-
2018
- 2018-01-18 TW TW111146907A patent/TWI832600B/zh active
- 2018-01-18 AR ARP180100119A patent/AR110755A1/es unknown
- 2018-01-18 TW TW107101790A patent/TWI788321B/zh active
- 2018-01-18 TW TW113101673A patent/TW202421659A/zh unknown
- 2018-01-19 CN CN201880007783.2A patent/CN111032690B/zh active Active
- 2018-01-19 CA CA3050884A patent/CA3050884A1/en active Pending
- 2018-01-19 MX MX2019008549A patent/MX2019008549A/es unknown
- 2018-01-19 US US15/875,125 patent/US10844115B2/en active Active
- 2018-01-19 KR KR1020197024021A patent/KR102613463B1/ko active Active
- 2018-01-19 MY MYPI2019006821A patent/MY194819A/en unknown
- 2018-01-19 IL IL268114A patent/IL268114B2/en unknown
- 2018-01-19 CN CN202410319667.1A patent/CN118121696A/zh active Pending
- 2018-01-19 BR BR112019013986-9A patent/BR112019013986A2/pt not_active IP Right Cessation
- 2018-01-19 EP EP18709437.0A patent/EP3571226A2/en active Pending
- 2018-01-19 IL IL317592A patent/IL317592A/en unknown
- 2018-01-19 KR KR1020237042558A patent/KR102755284B1/ko active Active
- 2018-01-19 UY UY0001037576A patent/UY37576A/es not_active Application Discontinuation
- 2018-01-19 JP JP2019539277A patent/JP7227138B2/ja active Active
- 2018-01-19 WO PCT/US2018/014350 patent/WO2018136698A2/en not_active Ceased
- 2018-01-19 AU AU2018210270A patent/AU2018210270A1/en not_active Abandoned
- 2018-01-19 MY MYPI2022003998A patent/MY207919A/en unknown
- 2018-01-19 KR KR1020257000987A patent/KR20250012197A/ko active Pending
- 2018-01-19 SG SG11201906663VA patent/SG11201906663VA/en unknown
-
2019
- 2019-07-17 MX MX2022008073A patent/MX2022008073A/es unknown
- 2019-11-20 ZA ZA2019/07673A patent/ZA201907673B/en unknown
-
2020
- 2020-10-23 US US17/079,285 patent/US12098194B2/en active Active
-
2023
- 2023-02-08 JP JP2023017271A patent/JP7597836B2/ja active Active
-
2024
- 2024-08-13 US US18/802,674 patent/US20250074975A1/en active Pending
- 2024-11-27 JP JP2024205967A patent/JP2025028981A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023058590A5 (https=) | ||
| JP2020505919A5 (https=) | ||
| JP7547581B2 (ja) | 腫瘍治療薬及びその応用 | |
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP4011914B2 (ja) | キメラポリペプチド、その製造方法、およびその使用 | |
| Plückthun et al. | New protein engineering approaches to multivalent and bispecific antibody fragments | |
| CN101445559B (zh) | 三聚体可溶抗体与其产生及使用的方法 | |
| JP2021087433A5 (https=) | ||
| JP2018502050A5 (https=) | ||
| JP2024532485A5 (https=) | ||
| FI3820894T3 (fi) | Mesoteliinia ja vastaavasti cd137:ää sitovia molekyylejä | |
| CN113195530B (zh) | 抗体融合蛋白、制备方法及其应用 | |
| WO2002033072A1 (fr) | Anticorps degrade, agoniste de tpo | |
| CN101981053A (zh) | 聚乙二醇化的AβFAB | |
| CN110234355A (zh) | 单体人IgG1 Fc和双特异性抗体 | |
| CN105377893A (zh) | 三聚体抗原结合分子 | |
| JP2023530663A5 (https=) | ||
| JP2023544211A5 (https=) | ||
| JP2026004299A5 (https=) | ||
| JP2018512124A5 (https=) | ||
| JP2022542670A5 (https=) | ||
| JP2019505565A5 (https=) | ||
| JP2023552462A5 (https=) | ||
| JP2025124718A5 (https=) | ||
| CN1381461A (zh) | 抗人肝癌单克隆抗体HAb18轻、重链可变区基因及其应用 |